Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Negatively charged microbial membrane lipids and anionic surface polymers are essential structural components of the bacterial cell envelope that serve as the primary docking sites for cationic antimicrobial agents. In Gram-negative bacteria, the outer membrane is rich in lipopolysaccharides (LPS) and phospholipids like phosphatidylglycerol and cardiolipin, which create a strong negative surface potential (Malanovic & Lohner, 2016). Gram-positive bacteria utilize anionic polymers such as teichoic acids and lipoteichoic acids to maintain cell wall integrity, regulate autolysins, and manage ion homeostasis (Swoboda et al., 2010). These molecules are critical for microbial survival, providing a protective barrier against environmental stressors and mediating interactions with the host immune system (Epand & Epand, 2011). Therapeutic agents like polymyxins and daptomycin exploit the electrostatic attraction between their cationic groups and these anionic targets to achieve selective binding over zwitterionic mammalian membranes (Zasloff, 2002). Upon binding, these drugs typically disrupt the membrane through pore formation, lipid displacement, or carpet-like disintegration, leading to rapid bactericidal effects (Yeaman & Yount, 2003). Because human cell membranes lack these high-density anionic polymers, these targets provide a significant basis for the development of selective anti-infective therapies.
Cationic antimicrobial agents bind to these anionic components via electrostatic attraction, leading to membrane permeabilization, displacement of essential ions, or physical disruption of the lipid bilayer (Zasloff, 2002; Yeaman & Yount, 2003).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Negatively charged microbial membrane lipids and anionic surface polymers.